Trawling for genes that predict response to breast cancer adjuvant therapy

Journal of Clinical Oncology

Volumn 22, Issue 12, 2004, Pages 2267-2269

  Ellis, Matthew ^a   Ballman, Karla ^b  

^a USA   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RELAPSE; EDITORIAL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; BIOLOGY; BREAST TUMOR; FEMALE; GENETICS; METHODOLOGY; NOTE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 2942729850     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.950     Document Type: Editorial

References (12)

1. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
2. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
3. Ayers M, Symmans WF, Stec J, et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-2293, 2004
4. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
5. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
6. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
7. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003
8. Stearns V, Singh B, Tsangaris T, et al: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9:124-133, 2003
9. Wasser K, Klein SK, Fink C, et al: Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 13:80-87, 2003
10. Dudoit S, Fridlyand J, Speed TP: Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 97:77-87, 2002
11. Simon R, Radmacher MD, Dobbin K: Design of studies using DNA microarrays. Genet Epidemiol 23:21-36, 2002
12. Paik S, Shak S, Tang G, et al: Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients: NSABP studies B-20 and B-14. Breast Cancer Res Treat 82:S10, 2003 (suppl 1, abstr 16)